Posted by Michael Wonder on 27 Sep 2023
IDEAYA receives fast track designation for potential first in class PARG inhibitor, IDE161, for treatment of pretreated, platinum-resistant advanced or metastatic ovarian cancer patients having tumours with BRCA1/2 mutations
26 September 2023 - On-going Phase 1 expansion, with focus in ER positive, HER2 negative, HRD positive breast cancer, HRD positive ovarian cancer and other HRD positive solid tumours, including endometrial and colon cancer.
IDEAYA Biosciences announces that the US FDA has granted fast track designation to IDEAYA's development program investigating IDE161, a potent and selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and poly (ADP-ribose) polymerase (PARP) inhibitor therapies.
